A 63-year-old woman with type 2 diabetes (diagnosed 8 years ago) and hypertension attends for review. HbA1c is 7.8% (62 mmol/mol) on metformin and gliclazide modified release. eGFR is 70 mL/min/1.73 m² and urinary albumin-creatinine ratio is 6 mg/mmol. She has a 5-year CVD risk of 14%. According to Australian diabetes guidance, which additional medicine is preferred for cardiovascular and renal risk reduction?